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ABSTRACT
Ovarian cancer is the seventh most common cancer worldwide for females and the 
most lethal of all gynecological malignancies. The treatment of ovarian cancer remains a 
challenge in spite of advances in debulking surgery and changes in both chemotherapy 
schedules and routes of administration. Cancer treatment has recently been improving 
with the introduction of targeted therapies to achieve greater specificity and less 
cytotoxicity. Both PARP inhibitors and MDM2-p53 binding antagonists are targeted 
therapeutic agents entered into clinical trials. This preclinical study evaluated the effect 
of Nutlin-3/RG7388 and rucaparib as single agents and in combination together in a 
panel of ovarian cancer cell lines. Median-drug-effect analysis showed Nutlin-3/RG7388 
combination with rucaparib was additive to, or synergistic in a cell type-dependent 
manner. Mechanism studies showed rucaparib alone had no effect on p53 stabilization 
or activity. Although treatment with Nutlin-3 or RG7388 induced stabilization of p53 
and upregulation of p21WAF1 and MDM2, the addition of rucaparib did not enhance the 
p53 activation seen with the MDM2 inhibitors alone. These results demonstrate that the 
synergistic effect on growth inhibition observed in the combination between rucaparib 
and Nutlin-3/RG7388 is not the result of increased p53 molecular pathway activation. 
Nevertheless, combined treatment of Nutlin-3/RG7388 with rucaparib increased cell 
cycle arrest and apoptosis, which was marked for A2780 and IGROV-1. These data 
indicate that combination treatment with MDM2 inhibitors and rucaparib has synergistic 
and dose reduction potential for the treatment of ovarian cancer, dependent on cell type.
INTRODUCTION
Ovarian cancer is the fifth leading cause of cancer-
related female deaths and was reported to be responsible 
for approximately 152,000 deaths worldwide in 2012 
[1]. Although up to 80% of patients with primary disease 
respond to first-line chemotherapy, relapse and resistance 
to further treatment is prevalent, leading to lack of long-
term benefit from treatment [2]. Mucinous and clear 
cell histological subtypes do not respond well to current 
chemotherapy strategies and are clinically challenging 
to treat [3, 4]. Different strategies have been developed 
to treat the recurrent and/or resistant disease, including 
targeted therapies such as angiogenesis inhibitors and 
poly(ADP-ribose) polymerase (PARP) inhibitors [5].
The inhibition of PARP enzymatic activity hinders 
DNA repair via the base excision repair (BER) pathway. 
For cells deficient in homologous DNA recombination 
repair (HRR) this results in multiple lethal DNA double-
strand breaks normally repaired by the HRR pathway. The 
tumor cells with BRCA1/2 mutation or other HRR defective 
status cannot efficiently repair these double-strand breaks, 
leading to cell death [6–8]. Another mode of action for 
PARP inhibitors is to trap PARP proteins at the sites of 
DNA damage, which is highly toxic to cells due to blockade 
of DNA replication and induction of a replication stress 
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response. PARP inhibitors proficiently result in synthetic 
lethality in tumor cells with BRCA1/2 or other HRR 
deficiencies, more than in normal DNA repair proficient 
cells [9, 10]. Rucaparib is one of a series of tricyclic 
benzimidazole carboxamide PARP inhibitors with a Ki of 1.4 
nM for PARP1 in a cell-free assay. It is a poly(ADP-ribose) 
polymerase (PARP) inhibitor successfully granted a license 
by the FDA and indicated as a monotherapy for the treatment 
of patients with a deleterious BRCA mutation (germline and/
or somatic) associated advanced ovarian cancer who have 
been treated with two or more chemotherapies [11].
Reactivation of wild-type p53 by preventing the 
protein-protein binding interaction between p53 and its 
negative regulator MDM2 induces the growth inhibitory 
and/or pro-apoptotic functions of p53, and has been 
demonstrated to have potential as a therapeutic strategy 
for non-genotoxic activation of p53. Nutlin-3 provided the 
mechanistic proof-of-concept for small molecule inhibition 
of the MDM2-p53 interaction and continues to be a 
useful reference tool compound; however, its potency and 
pharmacological properties are suboptimal for clinical use 
[12, 13]. RG7388, a second generation MDM2 inhibitor, 
was subsequently developed with superior potency, 
selectivity and oral bioavailability suitable for clinical 
development, with a cell-free IC
50
 value of 6 nM [14]. These 
compounds target a small hydrophobic pocket on MDM2, 
to which p53 normally binds, leading to p53 stabilization 
and upregulation of p53 downstream transcriptional targets 
involved in cell cycle arrest and/or apoptosis [15, 16].
Up to 50% to 60% of epithelial ovarian cancer 
is estimated to be deficient in HRR and hence likely to 
respond to PARP inhibitors [17]. The approximately 34% 
of ovarian cancer patients with tumors harboring wild-
type TP53 may benefit from MDM2 inhibitor treatment 
[16]. Combination chemotherapy for cancer treatment has 
a long established history, particularly for agents having 
different mechanism of action and non-overlapping 
toxicities. Utilizing targeted cancer therapeutic agents 
in combination is starting to be explored, although it has 
substantial complexity [18].
In the current study it was hypothesized that 
combination treatment of Nutlin-3/RG7388 with rucaparib 
further activates the p53 pathway by inhibition of PARP and 
results in enhanced induction and stabilization of p53 via 
Nutlin-3/RG7388 treatment to increase growth arrest and/
or apoptosis in wild-type TP53 ovarian cancer cell lines.
RESULTS
The growth inhibitory response of ovarian 
cancer cell lines to Nutlin-3/RG7388 and 
rucaparib
A sulforhodamine-B (SRB) assay was used to 
investigate growth inhibition by Nutlin-3/RG7388 or 
rucaparib for a panel of wild-type and mutant TP53 
ovarian cancer cell lines derived from tumors of different 
histological subtypes [19–22] (Figure 1 and Table 1). The 
GI
50
 values, required concentration of each compound 
leading to 50% growth inhibition, showed that wild-type 
TP53 ovarian cancer cell lines were significantly more 
sensitive to Nutlin-3/RG7388 compared to mutant, which 
is consistent with their mechanism of action (p<0.0001 
Mann-Whitney test) (Figure 1A & 1B). The GI
50
 values for 
wild-type TP53 cell lines for RG7388 and Nutlin-3 were 
in the nanomolar range ( 253.3 ± 73.1 (SEM) nM) and 
micromolar range (1.76 ± 0.51 (SEM) μM) respectively. 
In contrast, TP53 mutant cell lines had GI
50
 values greater 
than 10 μM (17.8 ± 2.9 (SEM) μM) for RG7388 and range 
21.2->30 μM for Nutlin-3 (Table 1).
For rucaparib, the cells were treated with a wide 
range of concentrations (0.4-25 μM) for 72 hours to 
construct growth inhibition curves and calculate the GI
50
 
values. The GI
50
 values significantly varied showing a 
range of responses, with A2780 (3.26±0.47 μM) and 
SKOV-3 (> 25 μM) as the most sensitive and resistant 
cell lines respectively. Although CP70 cells are derived 
from A2780, they have genetic alterations in addition to 
the difference in TP53 genomic status. In particular, CP70 
cells are mismatch repair (MMR)-deficient due to loss of 
the MLH1 gene and they are resistant to rucaparib even 
though A2780 cells are MMR-competent and sensitive 
to rucaparib. The CP70+ cell line is MLH1-corrected by 
chromosome 3 transfer into the CP70 cells and retains 
the heterozygous TP53 mutation. The A2780 and derived 
cell lines differ in growth rate, TP53 status and MLH1 
status and show differences in response to cisplatin and 
rucaparib, they are nevertheless all derived from the same 
tumor and thus overall are genetically closely related. The 
results of this study showed no relationship between the 
status of TP53 and response to rucaparib (Mann-Whitney, 
p>0.05) (Figure 1C).
Nutlin-3/RG7388 synergizes with rucaparib for 
growth inhibition of wild-type TP53 ovarian 
cancer cell lines
The effect of rucaparib in combination with Nutlin-3/
RG7388 was investigated for three wild-type TP53 
ovarian cancer cell lines using median-effect analysis. 
The sensitivity of the wild-type TP53 cell lines to growth 
inhibition during 72 hours exposure to rucaparib and 
Nutlin-3/RG7388 was determined as single agents, and in 
combination at 5 equipotent concentrations between 0.25× 
and 4× their respective GI
50
 concentrations for the A2780 
cell line. Owing to the high GI
50
 for IGROV-1 and OAW42 
in response to rucaparib, 3 equipotent concentrations 
between 0.25× and 1x their respective GI
50
 concentrations 
were used to evaluate the combination effect of rucaparib 
with Nutlin-3/RG7388. The effect of combined treatment 
was cell type dependent. The combination of Nutlin-3/
RG7388 with rucaparib at all concentrations led to greater 
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growth inhibition compared to either agent alone for the 
A2780, IGROV-1 and OAW42 cell lines, although the 
increase was smaller for the OAW42 cells (Figure 2). 
Combination treatment of rucaparib with Nutlin-3/RG7388 
at concentrations equal and lower than the individual 1x 
GI
50
 dose resulted in more growth arrest compared to doses 
higher than 1x GI
50
 for the A2780 cell line.
To determine whether the observed differences 
in growth inhibition were additive, synergistic or 
antagonistic, the data were analyzed using median-effect 
analysis and Combination Index (CI) values calculated. 
CI values for each constant ratio combination and at 
effect levels of ED
50
, ED
75
 and ED
90
 were computed and 
the average of CI values at ED
50
, ED
75
 and ED
90
 was also 
determined (Figure 3 & Table 2). Combined treatment of 
rucaparib with Nutlin-3/RG7388 ranged from additive to 
strong synergism based on the CI at ED
50
 and overall CI 
for A2780 and IGROV-1 cell lines, whereas only slight 
synergism to antagonism was observed for the OAW42 
cell line (Figure 3 & Table 2). Interestingly, rucaparib, 
Nutlin-3 and RG7388 had favorable Dose Reduction Index 
(DRI) values for combined treatment with all experimental 
Figure 1: The sensitivity to MDM2 antagonists, Nutlin-3 and RG7388, and rucaparib in a panel of wild-type and 
mutant TP53 ovarian cancer cell lines. Wild-type TP53 cell lines are significantly more sensitive to growth inhibition by (A) Nutlin-3 
(Mann Whitney test, p< 0.0001) and (B) RG7388 (Mann Whitney test, p< 0.0001) treatment for 72 hours compared to mutant TP53 cell 
lines. (C) The sensitivity to rucaparib is p53-independent. Data shown are the average of at least three independent experiments and error 
bars represent SEM.
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values ranging from 1.2-fold to 7.8-fold dose reduction 
(Table 3).
The effect of combination treatment with 
rucaparib and Nutlin-3/RG7388 on activation of 
the p53 pathway
Western blotting was used to investigate the 
effect of combination treatment on the p53 molecular 
pathway. Wild-type TP53 cell lines were treated with 
rucaparib, Nutlin-3 or RG7388 alone, and in combination 
at constant 1:1 ratios of 1/2x and 1x their respective 
GI
50
 concentrations for 4 hours. They were also treated 
with rucaparib, Nutlin-3 or RG7388 alone, and in 
combination at constant 1:1 ratios of 1x their respective 
GI
50
 concentrations for 24 hours, to test the induction of 
PUMA (BBC3) as a TP53-related pro-apoptotic gene. 
Western blot analysis showed that rucaparib treatment 
as a single agent had no effect on p53 stabilization, 
upregulation of p21WAF1, MDM2 or PUMA compared to 
DMSO control, nor generally did rucaparib increase the 
effect of the MDM2 inhibitors on the p53 pathway (Figure 
4 & Figure 5). Although rucaparib in combination with 
Nutlin-3/RG7388 appeared to increase stabilization of 
p53 and its downstream transcriptional targets in some 
cases in IGROV-1, otherwise there were no convincing 
differences. No evidence of synergy was observed at the 
molecular level to indicate that the mechanism of synergy 
for growth inhibition and apoptosis by rucaparib involved 
enhancement of the p53 pathway activation by MDM2 
inhibitors (Figure 4 & Figure 5).
Rucaparib in combination with Nutlin-3/RG7388 
induces cell cycle distribution changes and/
or apoptosis in wild-type TP53 ovarian cancer 
cell lines
Wild-type TP53 cell lines were treated with 
rucaparib and Nutlin-3/RG7388, alone and in simultaneous 
combination at constant 1:1 ratios of 1/2x and 1x their 
respective GI
50
 concentrations for 24, 48 and 72 hours. 
Then, they were analyzed by flow cytometry for cell cycle 
phase distribution changes and evidence of apoptosis in 
response to treatment.
Combination with Nutlin-3
Rucaparib on its own slightly increased the 
proportion of cells in G2/M phase and the number of 
SubG1 events in a dose and time-dependent manner. 
Combination treatment of rucaparib with Nutlin-3 resulted 
in an increased percentage of cells in the G2/M cell cycle 
phase compared to either agent alone, in a treatment time 
and dose-dependent manner for A2780 and IGROV-1 cell 
lines (Figure 6A & 6B). For the OAW42 cell line after 
24 hours, the combination treatment led to an increased 
proportion of the cell population in the G2/M phase of the 
cell cycle compared to Nutlin-3 as a single agent. After 
48 and 72 hours, there was little change in the cell cycle 
distribution following combination of rucaparib with 
Nutlin-3 compared to either agent alone (Figure 6C).
The basal levels of apoptosis, indicated by SubG1 
signals on FACS analysis, differed markedly between the 
cell lines, with much higher basal levels evident with the 
Table 1: GI50 concentrations of rucaparib, Nutlin-3 and RG7388 for the panel of ovarian cancer cell lines of varying 
TP53 status
Cell line TP53 status Histotype Rucaparib 
(μM)
Nutlin-3 
(μM)
RG7388 (μM)
A2780 Wild-type Undifferentiated [19] 3.26 ± 0.47 1.23 ± 0.23 0.11 ± 0.01
IGROV-1 Wild-type Mixed, EC with CCC/
UD [21]
11.34 ± 0.05 2.8 ± 0.48 0.35 ± 0.04
OAW42 Wild-type Serous 
Cystadenocarcinoma [20]
19.00 ± 0.58 1.3 ± 0.1 0.31 ± 0.04
CP70 Mutant (Heterozygous) 
c.514 G->T; p.Val172Phe
Undifferentiated [19] 17.00 ± 0.64 21.2 ± 2.5 11.7 ± 1.81
MLH1-Corrected 
CP70+
Mutant (Heterozygous) 
c.514 G->T; .Val172Phe
Undifferentiated [19] 14.00 ± 2.84 21.2 ± 1.22 14.5 ± 1.09
MDAH-2774 Mutant (Homozygous) 
c.818G->A; p.Arg273His
Endometrioid 
carcinoma [22]
6.92 ± 1.48 21.4 ± 0.9 20.7 ± 1.43
SKOV-3 Mutant (Homozygous) 
265delC; p.Pro89fsX33
Adenocarcinoma [20] >25 > 30 24.6 ± 1.54
Data represent the mean of at least 3 independent experiments ± SEM. EC, endometrioid carcinoma; CCC, clear cell 
carcinoma; UD, undifferentiated.
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Figure 2: Nutlin-3/RG7388 synergizes with rucaparib in wild-type TP53 ovarian cancer cells. (A) Growth inhibition curves 
of three wild-type TP53 cell lines exposed to Nutlin-3 and rucaparib alone, and in combination at constant 1:1 ratios of 0.25X, 0.5X, 1X, 
2X and 4X (A2780) or 0.25X, 0.5X and 1X (IGROV-1 & OAW42) their respective GI
50
 concentration for 72 hours. (B) Growth inhibition 
curves of three wild-type TP53 cell lines exposed to RG7388 and rucaparib alone, and in combination at constant 1:1 ratios of 0.25X, 0.5X, 
1X, 2X and 4X (A2780) or 0.25X, 0.5X and 1X (IGROV-1 & OAW42) their respective GI
50
 concentrations for 72 hours. Nut-3, Nutlin-3; 
RG, RG7388; Ruc, rucaparib.
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IGROV1 cells and least for the OAW42 cells. However, 
across all 3 cell lines, the trend was for combination 
treatments to induce an increased number of SubG1 
signals in a concentration and time-dependent manner 
(Figure 7).
Combination with RG7388
For A2780 cells, the combination of rucaparib 
with RG7388 increased the proportion of cells in G2/M 
phase and SubG1 signals compared to either agent alone, 
in a treatment time and dose-dependent manner. The 
combination treatment also decreased the proportion of 
cells in S-phase compared to either agent alone (Figure 
8A & 9A). In terms of the proportional distribution of 
IGROV-1 cells in G0/G1 or G2/M, the effect of rucaparib 
combination with RG7388 was time dependent. Combined 
treatment for 24 and 48 hours led to proportionally more 
cells in G0/G1 compared to the effect of rucaparib on its 
own and a higher proportion of cells in G2/M compared 
to the effect of RG7388 alone. After 72 hours treatment, 
the combination of rucaparib with RG7388 resulted in 
increased G2/M cell cycle arrest compared to RG7388 on 
its own, with little change in the percentage of cells in 
G0/G1 cell cycle compared to rucaparib alone. Combined 
treatments also increased the percentage of SubG1 
signals compared to either agent alone, in a time and 
dose-dependent manner (Figure 8B & 9B). For OAW42 
cells, combination of rucaparib with RG7388 led to 
proportionally more G2/M cells compared to either agent 
alone. It also decreased the percentage of cells in S-phase 
compared to either agent alone after 24 and 48 hours 
(Figure 8C & 9C).
Caspase 3/7 enzymatic activity was assessed to 
evaluate induction of apoptosis. Wild-type TP53 ovarian 
cancer cell lines were treated for 24 hours with 1x their 
respective Nutlin-3/RG7388 GI
50
 concentrations as a 
single agent and in combination with rucaparib (Figure 
10). For A2780 and OAW42 there was no significant 
increase in the caspase 3/7 activity in response to 
Nutlin-3/RG7388 alone. Also no significant increase 
was observed for the combination of Nutlin-3/RG7388 
with rucaparib compared with the effect of either agent 
alone in the A2780 and OAW42 cells. In contrast, there 
was a significant increase in caspase 3/7 activity in 
response to both Nutlin-3 and RG7388 as single agents 
in IGROV-1. Furthermore, the combination of Nutlin-3/
RG7388 with rucaparib resulted in more caspase 3/7 
activity in IGROV-1 compared to either agent alone 
(Figure 10).
DISCUSSION
PARP inhibitors have been developed over a number 
of decades and in more recent years have been shown to 
have efficacy as single agents against tumor cells with 
intrinsic deficiencies in DNA repair. They currently 
have been undergoing clinical trials in different types of 
cancers, including ovarian cancer [23–25]. Encouraging 
clinical trial results for the use of PARP inhibitors have 
been reported for ovarian cancer [11, 26]. The promising 
Figure 3: The CI values for Nutlin-3/RG7388 in combination with rucaparib at ED50 and the average of CI values at 
effect levels ED50, ED75 and ED90 in three wild-type TP53 ovarian cancer cell lines. Data are shown as the average of at least 
3 independent experiments and error bars represent SEM. CI, Combination Index; ED, Effective Dose.
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results showing activity of MDM2-p53 antagonists against 
wild-type TP53 ovarian cancer cell lines [16, 27] have 
prompted this investigation of combination treatment 
with rucaparib and Nutlin-3/RG7388 in a panel of wild-
type TP53 ovarian cancer cell lines. Mechanistically it 
was of interest to investigate the combined effect of PARP 
inhibition and MDM2-p53 binding antagonists on the p53 
pathway activation. This study evaluates for the first time 
the effect of the MDM2-p53 binding antagonists Nutlin-3 
and RG7388 in combination with rucaparib in wild-type 
Table 3: DRI values for growth inhibition by RG7388/Nutlin-3 in combination with rucaparib for the wild-type TP53 
ovarian cancer cell lines
Cell Line Combination Component
DRI
XGI50
0.25 0.5 1 2 4
A2780
Nutlin-3+Rucaparib
Rucaparib 3.1 2.7 3.0 2.5 1.6
Nutlin-3 5.00 3.9 3.6 2.6 1.6
RG7388+Rucaparib
Rucaparib 5.4 4.0 3.1 2.5 1.4
RG7388 5.1 4.4 3.0 2.4 1.6
IGROV-1
Nutlin-3+Rucaparib
Rucaparib 3.5 3.0 3.9 ND ND
Nutlin-3 3.5 2.8 3.3 ND ND
RG7388+Rucaparib
Rucaparib 5.7 5.0 3.7 ND ND
RG7388 2.7 3.9 7.8 ND ND
OAW42
Nutlin-3+Rucaparib
Rucaparib 2.3 1.6 1.9 ND ND
Nutlin-3 1.9 1.2 1.2 ND ND
RG7388+Rucaparib
Rucaparib 4.3 4.0 3.0 ND ND
RG7388 2.0 2.1 1.8 ND ND
The combined treatment was performed at the indicated fixed 1:1 ratios relative to their respective GI
50
 concentrations. 
DRI values were calculated for each constant ratio combination from the average of at least three independent experiments. 
Favorable DRI values (>1.0) are highlighted in bold font. DRI, Dose Reduction Index.
Table 2: Growth inhibition CI values for RG7388/Nutlin-3 in combination with rucaparib for the wild-type TP53 
ovarian cancer cell lines
Cell Line Combination
CI
CI ED50 CI ED75 CI ED90 CI Ave ED50-90XGI50
0.25 0.5 1 2 4
A2780
Nutlin-3+Rucaparib 0.4 0.5 0.5 0.6 1.0 0.4 0.6 1.1 0.7
RG7388+Rucaparib 0.4 0.4 0.6 0.7 1.2 0.3 0.7 1.9 0.9
IGROV-1
Nutlin-3+Rucaparib 0.6 0.7 0.6 ND ND 0.7 0.8 1.1 0.9
RG7388+Rucaparib 0.4 0.4 0.3 ND ND 0.5 0.4 0.7 0.5
OAW42
Nutlin-3+Rucaparib 0.9 0.7 0.9 ND ND 1.0 1.3 1.7 1.3
RG7388+Rucaparib 0.9 1.0 1.4 ND ND 1.2 3.2 4.6 2.4
The combined treatment was performed at the indicated fixed 1:1 ratios relative to their respective GI
50
 concentrations. CI 
values were calculated for each constant ratio combination and at effect levels ED
50
, ED
75
 and ED
90
 from the average of at 
least three independent experiments. CI Ave ED
50-90
 represents the average of CI values at effect levels of ED
50
, ED
75
 and 
ED
90
. CI range: < 0.1 very strong synergism; 0.1-0.3 strong synergism; 0.3-0.7 synergism; 0.7-0.85 moderate synergism; 
0.85-0.9 slight synergism; 0.9-1.1 nearly additive; 1.1-1.2 slight antagonism; 1.2-1.45 moderate antagonism; 1.45-3.3 
antagonism; 3.3-10 strong antagonism; > 10 very strong antagonism. Synergistic combinations are highlighted in bold font. 
CI, Combination Index; ED, Effective Dose.
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Figure 4: Combination of Nutlin-3/RG7388 with rucaparib increased stabilization of p53 and upregulation of its 
downstream targets, MDM2 and p21WAF1 compared to rucaparib on its own but not compared to Nutlin-3/RG7388. 
Total levels of p53, p21WAF1, MDM2 4 hours after the commencement of treatment with Nutlin-3 and RG7388 alone, and in combination 
with rucaparib at constant 1:1 ratios of 1/2X and 1X their respective GI
50
 concentration analyzed by western blot in three wild-type TP53 
ovarian cancer cell lines.
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TP53 ovarian cancer cell lines and explores the interplay 
between the p53 pathway and PARP dependent pathways 
modulated by rucaparib.
Within the panel of ovarian cancer cell lines 
studied, wild-type TP53 cell lines were significantly 
more sensitive to Nutlin-3 and the more potent RG7388 
compared to mutant TP53 cell lines, which is consistent 
with their mechanism of action [28]. Following the 
scheme suggested by Mukhopadhyay et al, the 10 μM cut-
off value was used to categorize cell lines into sensitive 
and resistant to PARP inhibitor [17]. Among the individual 
cell lines, A2780 and MDAH-2774 were sensitive (GI
50
 < 
10 μM) and other cell lines (IGROV-1, OAW42, CP70, 
MLH1-corrected CP70+ and SKOV-3) were resistant 
(GI
50
 > 10 μM). No relationship was found between the 
TP53 status of cells and response to rucaparib. These 
results are in line with those of previous studies reporting 
the sensitivity of A2780 and resistance of OAW42, 
IGROV-1, CP70 and SKOV-3 in response to rucaparib 
[29, 30]. Overall, the GI
50
 values for rucaparib across all 
cell lines were much higher than the concentration needed 
to reduce the cell-free enzymatic activity by half, Ki=1.4 
nM [31]. However, they were in the range of rucaparib 
concentrations achievable in vivo and used in clinical trials 
[10, 11, 26, 32].
To explore the potential mechanism involved 
in the sensitivity of A2780 and MDAH-2774 and 
resistance of other cell lines to rucaparib, the status 
of genes implicated as biomarkers in response to 
PARP inhibitors were studied [29, 33–37]. The most 
interesting finding is that the A2780 cell line was the 
most sensitive cell line even though among the relevant 
genes previously implicated in the sensitivity to rucaparib 
it has only a heterozygous mutation in PTEN (Deletion-
In frame, heterozygous, (c.380_388delGAAAGGGAC) 
(89682879_89682887delAGGGACGAA) (Supplementary 
Table 1). MDAH-2774 is an ovarian endometrioid tumor 
with mutant TP53 and KRAS [22].
Overall, the reasons for the greater sensitivity 
of A2780 and MDAH-2774 to rucaparib are not clear. 
Further research is needed to identify reliable biomarkers 
to stratify patients who will benefit from treatment with 
PARP inhibitors.
Resistance to MDM2-p53 binding antagonists has 
been suggested to be acquired by prolonged exposure 
of cells to sub-lethal doses through de novo inactivating 
TP53 mutations or selection of pre-existing subclones 
of TP53 mutant cells that might be present as a result of 
cancer cell genomic instability and tumor heterogeneity 
[38, 39]. Development of resistance to PARP inhibitors 
occurs through different mechanisms. For example, 
acquired resistance to PARP inhibitors resulting from a 
secondary mutation of the BRCA gene has been confirmed 
to occur in patients [10]. Combination therapy is suggested 
to delay or prevent drug resistance. Other major benefits 
of combination therapy are the potential for a synergistic 
therapeutic effect, or at least the possibility of dose and 
toxicity reduction [40, 41].
This study set out with the aim of assessing the 
effect of combination treatment of Nutlin-3 or RG7388 
with rucaparib in a panel of ovarian cancer cell lines of 
known TP53 status as combined targeted therapeutics. 
Updated results from the ARIEL2 clinical trial of 
rucaparib in 152 patients with wild-type BRCA1/2 who 
were sensitive to platinum reported a response rate of 
36% in those with BRCA-like DNA repair deficiency 
status. Less common mutations involved in Homologous 
Recombination Deficiency (HRD) and predictive of 
response to platinum may be present in almost one third 
(33%) of ovarian cancer patients [42]. Almost 30% of 
Figure 5: Combination of Nutlin-3/RG7388 with rucaparib increased upregulation of TP53 downstream target, 
PUMA compared to rucaparib on its own but not compared to Nutlin-3/RG7388. Total levels of PUMA 24 hours after 
the commencement of treatment with Nutlin-3 and RG7388 alone, and in combination with rucaparib at constant 1:1 ratios of 1X their 
respective GI
50
 concentration analyzed by western blot in three wild-type TP53 ovarian cancer cell lines.
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Figure 6: Combination of Nutlin-3 with rucaparib affects the cell cycle distribution. Wild-type TP53 ovarian cancer cells 
were treated for 24, 48 and 72 hours with Nutlin-3 or rucaparib alone and at constant 1:1 combination ratios of 1/2 X & 1X their respective 
GI
50
 concentrations. (A) A2780 cell line, (B) IGROV-1 cell line, (C) OAW42 cell line. Nut-3, Nutlin-3; Ruc, rucaparib; *, p < 0.05. Data 
are shown as the average of at least 3 independent experiments and error bars represent SEM.
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Figure 7: Combination of Nutlin-3 with rucaparib affects the apoptotic endpoints. FACS analysis for SubG1 events. Wild-
type TP53 ovarian cancer cells were treated for 24, 48 and 72 hours with Nutlin-3 or rucaparib alone and at constant 1:1 combination ratios 
of 1/2 X & 1X their respective GI
50
 concentrations. (A) A2780 cell line, (B) IGROV-1 cell line, (C) OAW42 cell line. Nut-3, Nutlin-3; Ruc, 
rucaparib; *, p <0.05; **, P < 0.01. Data are shown as the average of at least 3 independent experiments and error bars represent SEM.
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Figure 8: Combination of RG7388 with rucaparib affects the cell cycle distribution. Wild-type TP53 ovarian cancer cells 
were treated for 24, 48 and 72 hours with RG7388 or rucaparib alone and at constant 1:1 combination ratios of 1/2 X & 1X their respective 
GI
50
 concentrations. (A) A2780 cell line, (B) IGROV-1 cell line, (C) OAW42 cell line. RG, RG7388; Ruc, rucaparib; *, p <0.05; **, P < 
0.01. Data are shown as the average of at least 3 independent experiments and error bars represent SEM.
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Figure 9: Combination of RG7388 with rucaparib affects the apoptotic endpoints. FACS analysis for SubG1 events. Wild-
type TP53 ovarian cancer cells were treated for 24, 48 and 72 hours with RG7388 or rucaparib alone and at constant 1:1 combination ratios 
of 1/2 X & 1X their respective GI
50
 concentrations. (A) A2780 cell line, (B) IGROV-1 cell line, (C) OAW42 cell line. RG, RG7388; Ruc, 
rucaparib; *, p <0.05. Data are shown as the average of at least 3 independent experiments and error bars represent SEM.
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ovarian cancers include histological subtypes other than 
high grade serous and these are mostly TP53 wild-type. 
Thus nearly 10% of ovarian cancer patients (one third 
of the 30% not high grade serous) who are likely to be 
sensitive to both MDM2 inhibitors and rucaparib may 
benefit from combination treatment with these agents. In 
addition, almost 4% of high grade serous ovarian cancers 
nevertheless have wild-type TP53 and these mostly have 
BRCA1/2 mutation or other HRD status [42], rendering 
them sensitive to both MDM2 inhibitors and rucaparib and 
therefore likely to benefit from the combined treatment. 
Furthermore, those ovarian tumours which include a 
histological mixture of high grade serous with clear cell, 
mucinous, endometrioid or low grade serous might gain 
benefit from this combination treatment to target the 
different components.
Overall, the effect of combined treatment was 
cell type and exposure time dependent, with a higher 
synergistic effect for the combination of Nutlin-3/RG7388 
with rucaparib for A2780 and IGROV-1 cell lines. 
Interestingly, although both IGROV-1 and OAW42 were 
resistant to rucaparib, there was nevertheless a synergistic 
effect for the combination of Nutlin-3/RG7388 with 
rucaparib. A possible explanation for this is that the defects 
conferring sensitivity to PARP inhibitors as single agents 
may be different from those which play an important role 
in the response to the combination treatment. For example, 
serious deficiencies in HRR may affect the sensitivity to 
PARP inhibitors as single agents, while mild defects in 
HRR may have no effect on response to PARP inhibitors 
alone but may nevertheless influence the effect of 
combination treatments [8, 29]. Another possibility is that 
different p53-dependent off-target effects of these MDM2 
inhibitors [43, 44] and/or off-target effects of rucaparib 
with respect to PARP1 and PARP2 may influence the 
growth inhibitory effect of combined treatment compared 
to rucaparib as a single agent [45, 46].
An important and clinically relevant finding from 
the data is the favorable DRI values in both combination 
treatment of Nutlin-3 or RG7388 with rucaparib. Additive 
and even mildly antagonistic results of combined 
treatment can nevertheless be of potential clinical use 
due to favorable DRI values [47, 48]. These favorable 
DRI values demonstrate that combination of Nutlin-3 or 
RG7388 with rucaparib has the potential to reduce the 
dose of drugs in most cases to achieve the same overall 
level of effect, indicating a potential clinical benefit of 
combining these therapeutic agents, particularly when they 
have differing dose limiting toxicities.
Rucaparib on its own had no effect on p53 
stabilization and upregulation of its downstream targets 
p21WAF1, MDM2 and PUMA across all three cell lines. 
Combination treatment of Nutlin-3 or RG7388 with 
rucaparib induced stabilization of p53 and upregulation 
of p21WAF1, MDM2 and PUMA compared to rucaparib on 
its own, whereas rucaparib had no enhancement of the 
p53 activation by MDM2 inhibitors alone. These results 
demonstrate that the synergistic effect on growth inhibition 
observed for the combination of rucaparib and Nutlin-3/
RG7388 is not the result of an accentuated p53 response 
and hence not related to the p53 molecular pathway. The 
interplay between PARP and p53 is controversial which 
may be related to the type of DNA damage, type of PARP 
inhibitors and intensity of replicative stress [49, 50].
Individually, Nutlin-3 and RG7388 induced cell 
cycle arrest in wild-type TP53 ovarian cancer cell lines 
in a time and dose-dependent manner. Rucaparib had 
little effect on the cell cycle distribution for IGROV-1 and 
OAW42 cell lines, which is in agreement with the results 
obtained by Porcelli et al. [51] that indicated no effect 
Figure 10: Combinations of Nutlin-3 or RG7388 with rucaparib affect caspase3/7 activity. The wild-type TP53 ovarian 
cancer cells treated at constant 1:1 ratios of 1x their respective GI
50
 concentrations of Nutlin-3, RG7388 or rucaparib alone, and in 
combination for 24 hours. Caspase 3/7 activity is represented as fold change relative to DMSO solvent control. *, The single star represents 
a significant increase in the caspase3/7 activity compared to DMSO control (p<0.05); **, The double stars represent a significant increase 
in the caspase3/7 activity compared to Nutlin-3, RG7388 or rucaparib alone (p<0.01).
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of rucaparib on the cell cycle progression of pancreatic 
cancer cells. However, in the current study rucaparib 
significantly decreased the proportion of cells in S-phase 
in A2780 cells, consistent with a recent study indicating 
a robust decrease in the percentage of cells in S-phase 
following treatment of U2OSDR-GFP cells with olaparib 
[50]. Furthermore, there was only a slight increase in the 
SubG1 cell subpopulation across all cell lines treated with 
rucaparib compared to DMSO control, suggesting that 
cells are not undergoing apoptosis. These results are in line 
with those of Jelinic and Levine who observed low SubG1 
events in cancer cells treated with olaparib or veliparib 
[49].
Across all three cell lines, combined treatment of 
Nutlin-3/RG7388 with rucaparib increased the proportion 
of cells in the G2/M phase of the cell cycle, which was 
marked for A2780 and IGROV-1. This can be explained 
by induction of p21WAF1 expression in response to 
MDM2 inhibitors and its critical role in cell cycle arrest 
in G2/M by inhibiting mitotic Cdk complexes and Rb 
phosphorylation [52]. Also, p53-mediated repression of 
FoxM1 results in the maintenance of a stable G2/M arrest 
which is partially p21 dependent [53]. The increased 
proportion of cells in G2/M phase following PARP 
inhibitor treatments may reflect their mechanism of action 
during DNA replication in S-phase, which is to trap PARP-
1 and -2 to DNA and induce a replicative stress response 
[50]. Combination treatment with Nutlin-3 or RG7388 and 
rucaparib also led to more SubG1 events and/or higher 
levels of caspase 3/7 activity compared to either agent 
alone in a cell type dependent manner which was marked 
for IGROV-1 cells.
In conclusion, the present study demonstrates 
that combination treatment with MDM2 inhibitors and 
rucaparib has synergistic and/or dose reduction potential 
dependent on cell genotype and compound and merits 
further investigation. Monitoring HRR status, cell cycle 
markers, PARP expression and PARP activity are likely 
to provide additional useful information to assess the 
effectiveness of PARP inhibitors. This information may 
be helpful to stratify the patients who might benefit from 
PARP inhibitors and their potential combination with the 
emerging class of MDM2 inhibitors.
MATERIALS AND METHODS
Chemicals and antibodies
Nutlin-3, a 1:1 mixture of the active enantiomer 
Nutlin-3a and the inactive enantiomer Nutlin-3b, was 
purchased from NewChem (Newcastle, UK) and RG7388 
(Idasanutlin) was synthesized by Ruth Bawn and Amy 
Heptinstall within the Newcastle Drug Discovery Group. 
Both were dissolved in dimethyl sulfoxide (DMSO). 
Rucaparib was kindly supplied by Clovis Oncology, and 
prepared in 10mM stocks solubilized in DMSO.
Cell lines
The ovarian cancer cell lines used in this study, their 
TP53 status and histological subtype are listed in Table 1. 
All cell lines were sourced from the NICR authenticated 
cell bank and regularly tested for Mycoplasma. A2780, 
IGROV-1, OAW42 and CP70 were cultured in RPMI-
1640 supplemented with 10% (v/v) FBS and 5% (v/v) 
penicillin/streptomycin. The CP70 cell line harbors a 
heterozygous TP53 mutation (c.514 G->T, p.Val172Phe) 
[54]. The MLH1-corrected CP70+ cell line was grown 
in RPMI-1640 supplemented with 10% (v/v) FBS and 
Hygromycin B (200 μg/ml: Life Technologies, Inc.) [54]. 
This cell line has the heterozygous TP53 mutation (c.514 
G->T, p.Val172Phe). SKOV-3 and MDAH-2774 cell lines 
were cultured in DMEM supplemented with 10% and 5% 
(v/v) FBS and penicillin/streptomycin respectively. As 
information on the TP53 status of SKOV-3 and IGROV-1 
in the literature was contradictory, sequencing was 
performed. The results of PCR-based Sanger sequencing 
of TP53 exon 5 and exon 4 confirmed the wild-type TP53 
status of the IGROV-1 cell line (Supplementary Figure 1). 
For the SKOV-3 cell line, frame shift deletion (c.265delC, 
p.Pro89fsX33) was confirmed in TP53 exon 4 and no 
substitution mutation (c.179 A->G) was detected in TP53 
exon 5 (Supplementary Figure 2). The MDAH-2774 cells 
were confirmed to harbor a TP53 mutation located in exon 
8 (c.818G->A, p.Arg273His) [55].
Growth inhibition assays and median-effect 
analysis
The GI
50
 values, the required concentrations of 
each compound leading to 50% growth inhibition, were 
determined by Sulforhodamine B (SRB) growth inhibition 
assays for drug exposure over 72 hours and the absorbance 
of the re-dissolved SRB protein stain was measured at 570 
nm using a 96-well plate spectrophotometer (Spectramax 
250 Molecular Devices) [56]. Growth curves were 
constructed using GraphPad Prism statistical analysis 
software version 5.04. For combination treatment of 
Nutlin-3 or RG7388 with rucaparib, the wild-type TP53 
cell lines were treated for 72 hours with each agent 
alone and in combination simultaneously at constant 
1:1 ratios of 0.25x, 0.5x, 1x, 2x, and 4x their respective 
GI
50
 concentrations. Median-effect analysis was used to 
calculate Combination Index (CI) and Dose Reduction 
Index (DRI) values [57] using CalcuSyn software v2 
(Biosoft, Cambridge, UK).
Western blotting
Lysis buffer (12.5 ml Tris HCL, 2g SDS, 10 
ml Glycerol, 67.5 ml Distilled Water) was used to 
harvest whole-cell lysates, followed by sonication. The 
concentration of protein in the cell lysates was estimated 
by using a bicinchoninic acid (BCA) assay. Novex® 
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4-20% Tris-Glycine 12-well polyacrylamide gradient 
gels (Invitrogen, UK) were used to separate proteins. 
The separated proteins were transferred by perpendicular 
electrophoresis to a nitrocellulose Hybond™ C membrane 
(Amersham, Buckinghamshire, UK). Monoclonal Mouse 
Anti-Human primary antibodies Actin 1:1000 (#: A4700, 
Sigma-Aldrich), MDM2 1:300 (#: OP46-100UG, Merck 
Millipore), p21WAF1 1:100 (#: OP64, Calbiochem), PUMA 
1:1000 (#dd716, Santa Cruz Biotechnology) and p53 
1:500 (#: NCL-L-p53-DO7, Leica Microsystems Ltd.) 
were used. Secondary goat anti-mouse HRP-conjugated 
antibodies (#: P0447/P0448, Dako) were used at 1:1000. 
All antibodies were diluted in 5% milk/1XTBS-Tween 
(w/v). Enhanced chemiluminescence (GE Life Sciences) 
and X-ray film (Fujifilm) were used to visualize the 
proteins.
Flow cytometry
Cells were treated with Nutlin-3, RG7388 and 
rucaparib alone and with combinations of Nutlin-3 or 
RG7388 with rucaparib simultaneously at constant 1:1 
ratios of 0.5x and 1x their respective GI
50
 concentrations 
for 24, 48 and 72 hours. Harvested cells, both floating and 
adherent, were washed with PBS and resuspended in 500 
μL PBS with 1mg/mL sodium citrate (Sigma, St Louis, 
MO), 100 μg/mL propidium iodide (Sigma), 200 μg/mL 
RNAse A (Sigma) and 0.3% Triton-X (Sigma). Samples 
were analyzed on a FACSCalibur™ flow cytometer using 
CellQuest Pro software (Becton Dickinson, Oxford, UK). 
Cell cycle distribution was determined using Cyflogic 
(CyFlo Ltd, Turku, Finland).
Caspase 3/7 activity assay
Caspase 3/7 activity was measured using a Caspase- 
Glo 3/7 assay following the manufacturer’s instructions 
(Promega, Southampton, UK).
Statistical analysis
All statistical tests presented were carried out using 
GraphPad Prism version 5.04 software. A p-value of <0.05 
was considered to be statistically significant based on at 
least n=3 experimental repeats.
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